<DOC>
	<DOCNO>NCT01079130</DOCNO>
	<brief_summary>This study compare 14-day bronchodilator efficacy indacaterol placebo salmeterol</brief_summary>
	<brief_title>Efficacy Safety Different Doses Indacaterol</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Patients diagnosis asthma , : 1 . Receiving daily treatment inhale corticosteroid regimen stable least month prior screen 2 . Prebronchodilator force expiratory volume 1 second ( FEV1 ) screen ≥50 ≤90 % predict normal 3 . An increase ≥12 % ≥200 mL FEV1 prebronchodilator value within 30 minute inhale albuterol Smoking history &gt; 10 packyears Patients diagnosis chronic obstructive pulmonary disease ( COPD ) Patients seasonal allergy whose asthma likely deteriorate study period Patients experience severe asthma attack/exacerbation require hospitalization 6 month prior screen Patients intubation severe asthma exacerbation Patients emergency room visit asthma attack/asthma exacerbation within 6 week prior screen Patients respiratory tract infection within 6 week prior screen Patients concomitant pulmonary disease Patients diabetes Type I uncontrolled diabetes Type II Any patient lung cancer history lung cancer Patients history certain cardiovascular comorbid condition Patients ever receive currently receive omalizumab chronic oral corticosteroid therapy Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Indacaterol</keyword>
	<keyword>asthma</keyword>
	<keyword>salmeterol</keyword>
</DOC>